SCR7 pyrazine is a potent and selective inhibitor of non-homologous end joining (NHEJ),useful tool compound for CRISPR editing.

＞98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

SCR7; SCR-7; SCR 7.

Powder

DMSO : ≥ 45 mg/mL

DNA Ligase IV,CRISPR/Cas9

SCR7 inhibits joining of double-strand breaks (DSBs) in cell-free repair system. SCR7 blocks Ligase IV-mediated joining by interfering with its DNA binding but not that of T4 DNA Ligase or Ligase I. SCR7 inhibits NHEJ in a Ligase IV-dependent manner within cells, and activates the intrinsic apoptotic pathway. Results show a dose-dependent decrease in cell proliferation of MCF7, A549, and HeLa with an IC50 of 40, 34, and 44 μM, respectively, which is further confirmed by DIC imaging in MCF7. T47D, A2780, and HT1080 are also sensitive to SCR7, with an IC50 of 8.5, 120, and 10 μM, respectively.

SCR7 treatment (10 mg/kg, six doses) significantly reduces breast adenocarcinoma-induced tumor. Untreated tumor animals survived only for 52 days, whereas treated animals exhibit ~4-fold increase in lifespan.